Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes the patterns of clinical response in patients with severe alopecia areata treated with baricitinib over 52 weeks, based on integrated data from two Phase 3 trials.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study found that twice-daily oral baricitinib at a 2-mg dose showed promising results in treating refractory alopecia areata, particularly among Chinese patients, with 64% achieving significant hair regrowth, although none attained complete hair regrowth. Adverse events were mild and included nausea and folliculitis.

In this study, baricitinib, a JAK inhibitor, was found to significantly improve scalp hair regrowth in both adults and adolescents with severe alopecia areata, with many achieving nearly full regrowth by weeks 36 or 52.

This study found that Rubus coreanum extract promotes hair growth in mice, but its effects are not due to inhibition of specific enzymatic activities or growth factor expression.

This literature review concludes that mulberry, with its rich anthocyanin, phenolic, and antioxidant content, may serve as an effective adjuvant therapy for preventing and managing obesity by reducing body fat levels.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

In this study, baricitinib 4 mg led to greater scalp, eyebrow, and eyelash hair regrowth in severe alopecia areata patients than baricitinib 2 mg at weeks 36 and 52.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This study found that the superior growth and higher zinc uptake of wild-type barley compared to its root-hairless mutant in zinc-deficient soil is mainly due to greater root surface area from root hairs.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This study compared the antioxidant and antidiabetic activities of Hibiscus rosa-sinensis leaf extract and Eclipta alba bark extract, finding that Hibiscus rosa-sinensis exhibited greater antidiabetic activity, whereas Eclipta alba demonstrated stronger antioxidant activity.

In this study, baricitinib showed effectiveness and good tolerability in treating severe alopecia areata over 52 weeks.

The researchers developed a hair serum using rosemary essential oil and ficus bengalensis aerial roots, and successfully evaluated its viscosity, pH, and color.

Pink berry extract effectively treats scalp issues from frequent head covering.

In this study, data from multiple sources found that Baricitinib significantly promoted hair regrowth and improved patient-reported outcomes in those with severe alopecia, with minimal side effects, over a 36-week period.

This case report highlights the successful treatment of a 37-year-old male with steroid-resistant beard alopecia areata using baricitinib, a JAK-1/2 inhibitor, over 9 months, resulting in reduced hair loss and improved hair density.

This study found that ethanol and water extracts of Albizia saponaria bark significantly stimulated hair growth in male rabbits over 24 days.

This review discusses the potential health benefits of Indian gooseberries, including blood glucose management and cardiovascular health, and highlights the need for additional research; no new clinical results are reported.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

In a randomized controlled trial, King et al. found that oral baricitinib at doses of 2 mg and 4 mg significantly improved hair regrowth in adults with alopecia areata compared to placebo, supporting its efficacy and safety for those with substantial scalp hair loss.

This study evaluated herbal cosmetic products used in Turkiye, identifying 140 plant species and highlighting walnut, common nettle, and grape as popular for various traditional uses.

This review explores the bioactive mechanisms of black mulberry (Morus nigra L.) and its potential as a natural treatment for scalp issues like dandruff and hair loss, highlighting its antibacterial, anti-inflammatory, antioxidant properties, and capacity to improve scalp blood flow.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.